Biocodex launches Fullify, a gut-brain axis probiotic for appetite control. Find out what this means for weight loss, microbiome science, and the supplement industry.
Can TPC-026 fill the gap after GLP-1s? Find out how TETRAPHARM’s novel compound could reshape long-term metabolic care.
Genentech’s CT-388 hit 22.5% weight loss in Phase II. Find out what this means for obesity drugs, clinical durability, and market strategy in 2026.
Innovent Biologics has reported that mazdutide, its dual GLP-1 and glucagon receptor agonist, achieved statistically significant reductions in both body mass index and weight in Chinese adolescents with obesity during a 12-week Phase 1b clinical trial. The trial met its primary endpoint, demonstrated a favorable safety profile, and paves the way for a Phase 3 […]